Doctors Rethink How Autistic Patients Weigh Life-or-Death Cancer Choices

When a man with autism spectrum disorder arrived at a palliative care clinic at Emory University, his question was deceptively simple: did he have the capacity to decline further treatment for his progressive prostate cancer? What followed, according to a case report published in the Journal of General Internal Medicine, was a careful unraveling of how modern medicine handles one of its most delicate tasks—shared decision-making—for patients whose brains process information, sensation, and communication in profoundly different ways. The case, described by physicians Ryanne Lehenaff, Ronnye Rutledge, Priscilla Kim, and Emily Pinto Taylor, offers a rare technical window into a gap that has quietly widened as the first large generations of autistic adults reach the ages where serious illness becomes common.

The clinical stakes are considerable. Shared decision-making is the backbone of contemporary serious illness care: clinicians lay out medically reasonable options, elicit patient values, and together arrive at a plan that reflects what matters most to the person in the chair. To do this, medicine has built an arsenal of validated instruments—structured conversation guides, advance care planning tools, and decision aids tested in diverse populations. Yet as the Emory team emphasizes, not one of these tools has been validated in neurodivergent populations. The frameworks assume a particular style of cognition: comfort with abstraction, tolerance for open-ended hypotheticals, and fluency in the ambiguous language of goals and values. For many autistic patients, those assumptions simply do not hold.

Autism spectrum disorder, classified among neurodevelopmental disorders in the Diagnostic and Statistical Manual of Mental Disorders, is defined by differences in social communication and interaction alongside restricted, repetitive patterns of behavior and interest. Research reviewed by the authors points to specific cognitive profiles that matter in the clinic: difficulties with conceptual reasoning and problem solving in some autistic adults, documented challenges in decision-making that people with autism themselves report, and structural language differences that can make figurative or indirect phrasing hard to parse. A question like “what would quality of life mean to you?”—a staple of palliative conversations—asks the patient to navigate abstraction, hypothetical futures, and social convention simultaneously. The authors argue that such questions can obscure rather than reveal a neurodivergent patient’s true preferences.

The Emory case illustrates how these abstract difficulties become concrete at the bedside. The patient, a man with autism spectrum disorder and multiple comorbid neuropsychiatric conditions, faced a genuinely consequential choice about deferring treatment for progressive prostate cancer. His care team was asked to assess whether he possessed decision-making capacity—a legal and clinical determination that hinges on whether a patient can understand relevant information, appreciate its application to their own situation, reason through the options, and communicate a consistent choice. Capacity assessments are already among the most nuanced evaluations in medicine; layered with autism and co-occurring psychiatric conditions, the authors write, they demand careful thought and innovative communication strategies rather than a checklist.

From this single case, the team distilled a set of practical strategies that function almost as a protocol for neurodivergence-informed serious illness conversations. First, use visual aids: converting verbal abstractions into concrete, visual representations of options, timelines, and trade-offs grounds the discussion in information the patient can directly examine. Second, avoid abstractions: instead of asking about values in the abstract, clinicians should anchor questions in specific, concrete scenarios—what a particular treatment would involve day to day, what a given side effect would actually feel like. Third, maintain a low-stimulation sensory environment: fluorescent lighting, noise, and crowded rooms are not trivial irritants for autistic patients but genuine barriers that can degrade attention, processing, and ultimately the quality of the decision itself.

The fourth strategy involves people. The authors highlight engaging key stakeholders—family members and caregivers—as partners in the decision-making process. This is not a retreat from patient autonomy but a recognition of supported decision-making, an approach increasingly endorsed in policy for people with intellectual and developmental disabilities. Rather than defaulting to guardianship or substituted judgment, supported decision-making keeps the patient at the center while allowing trusted people to help interpret information, frame options, and communicate preferences. In this case, the patient’s mother was intimately involved in his care and, the authors note, agreed to share the story so that other clinicians and families could learn from it.

The timing of this report is not incidental. The authors point to a rising public health concern: as adults living with autism spectrum disorder age, the population confronting cancer diagnoses, complex treatment choices, and end-of-life planning is growing rapidly. Studies cited in the report document persistent health disparities for adults with intellectual and developmental disabilities, and surveys of autistic adults in the United Kingdom have found that healthcare adjustments—simple accommodations that improve access—are often important but frequently unavailable. Physician knowledge and experience with autistic adults remains uneven; a large integrated healthcare system study found substantial gaps in how prepared physicians felt to care for this population. The convergence of an aging neurodivergent cohort with an unadapted healthcare system is, the authors suggest, a problem medicine has not yet confronted at scale.

The report also situates the case within a broader landscape of serious illness communication tools. Structured approaches such as the Serious Illness Conversation Guide, community-based advance care planning programs like PREPARE and Project Talk, and initiatives such as The Conversation Project and Stanford’s Letter Project have all improved communication for many patients and their surrogates. Frameworks like Autistic SPACE, developed to meet the needs of autistic people in healthcare settings, address environmental and communication adjustments more broadly. But the Emory authors stress that none of the patient-facing serious illness tools has been tested specifically for neurodivergent users, leaving clinicians to improvise—case by case, conversation by conversation—without evidence-based guidance.

What emerges from the report is less a formula than a philosophy: treat communication as a clinical intervention in its own right, one that must be engineered for the individual patient. The complex impact of multiple comorbid neuropsychiatric conditions, the authors note, compounds the challenge, because capacity, communication style, and preferences can shift with psychiatric symptoms, sensory state, and context. A decision that seems settled in a quiet clinic room may need to be revisited in a hospital corridor. The strategies they propose—visual supports, concrete language, sensory regulation, and stakeholder involvement—are presented not as accommodations bolted onto standard care but as the core mechanism by which genuine shared decision-making becomes possible for neurodivergent patients.

For a medical culture increasingly attuned to neurodiversity, the case is a pointed reminder that equity in serious illness care is not only about access to treatments but access to the conversation itself. The authors thank their patient and his mother for allowing the story to be told, and their closing implication is clear: as this population ages, the field will need validated tools, trained clinicians, and systems designed from the ground up to support autistic and otherwise neurodivergent patients through the hardest decisions medicine asks anyone to make. Until then, the Emory team’s blueprint—concrete, visual, sensory-aware, and collaborative—offers clinicians a place to start.

Subject of Research: Shared decision-making and decision-making capacity in serious illness care for patients with autism spectrum disorder and neurodivergence

Article Title: Supporting Patients with Autism Spectrum Disorder and Neurodivergence in Serious Illness Decision-Making

Article References: Lehenaff, R., Rutledge, R. C., Kim, P., & Pinto Taylor, E. (2026). Supporting Patients with Autism Spectrum Disorder and Neurodivergence in Serious Illness Decision-Making. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10915-4

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10915-4

Keywords: autism spectrum disorder, neurodivergence, shared decision-making, palliative care, prostate cancer, decision-making capacity, health communication, advance care planning, supported decision-making, health disparities, developmental disabilities, serious illness conversations